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Abstract 
The promyelocytic leukemia protein (PML) is involved in many cellular processes including 
cell cycle progression, DNA damage response, transcriptional regulation, viral infection, and 
apoptosis. These cellular activities often rely on the localization of PML to unique subnuclear 
structures known as PML nuclear bodies (NBs). More than 50 cellular proteins are known to 
traffic in and out of PML NBs, either transiently or constitutively. In order to understand the 
dynamics of these NBs, it is important to delineate the regulation of PML itself. PML is sub-
ject to extensive regulation at transcriptional, post-transcriptional, and post-translational 
levels. Many of these modes of regulation depend on the cellular context and the presence 
of extracellular signals. This review focuses on the current knowledge of regulation of PML 
under normal cellular conditions as well as the role for regulation of PML in viral infection 
and cancer. 
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Discovery of PML 
PML was discovered due to its role in the onco-
genesis of Acute Promyelocytic Leukemia (APL). The 
PML gene is involved in a chromosomal translocation 
with the gene for retinoic acid receptor α (RARα). This 
translocation results in the expression of the fusion 
proteins PML-RARα and RARα-PML (1). The expres-
sion of these proteins is the driving force in the de-
velopment of APL. The two best treatments for APL 
are with the natural RARα ligand, all-trans retinoic 
acid (ATRA), or with arsenic trioxide (As2O3) (2). In-
terestingly, in APL patients where PML-RARα is ex-
pressed, the normal localization of PML into PML 
NBs in the cell is disrupted (1; 3; 4). The use of either 
of these treatments leads to restoration of PML NBs 
(5). While these are secondary effects of ATRA treat-
ment, As2O3 targets the PML portion of PML-RARα 
directly (6). This activity will be investigated later in 
this review.  
PML Nuclear Bodies 
PML NBs (also known as PODs and ND10) are 
discrete subnuclear structures suggested to act as 
cellular organizing centers for the coordinated regu-
lation of different processes including transcriptional 
regulation, DNA damage response, apoptosis, and 
senescence. PML NBs range in size from 0.2 to 1 μm 
and in number from 1 to 30 bodies per cell (7). More 
than 50 proteins are known to localize in PML NBs 
either constitutively or transiently, including p53, 
CBP/p300, Daxx, BLM, Pin1, HDAC7, and pRB (8-13). 
Furthermore, while some of these proteins, such as 
Daxx, have been shown to bind to PML directly, many 
are recruited to PML NBs via indirect interaction with 
another NB component. PML NBs are absent in Int. J. Biol. Sci. 2009, 5 
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PML-/- primary cells, but can be reconstituted by the 
expression of exogenous PML (8; 14), indicating that 
PML is essential for the formation and integrity of 
PML NBs.   
The accumulation of PML can be regulated in 
response to specific cellular stimuli at multiple steps, 
namely at transcriptional, post-transcriptional and 
post-translational events. These regulatory events not 
only control PML protein levels, but also modifica-
tions of PML that are important for both NB forma-
tion and interactions with other proteins.  
Transcriptional Control of PML Expression 
Transcriptional induction of PML is an impor-
tant mechanism by which extracellular signals can 
orchestrate a response involving PML NBs. Inter-
ferons (IFN) have been shown to activate PML tran-
scription, leading to increased PML protein levels, 
nuclear body size and number in a variety of cell 
types (15-19). Both type I and type II IFNs (α, β, and γ) 
are able to induce expression of PML transcripts. This 
is mediated through binding of IFN-stimulated tran-
scription factors, known as signal transducers and 
activators of transcription (STATs), to both an 
IFN-α/β stimulated response element (ISRE) and an 
IFN-γ activation site (GAS) in the first exon of PML 
(16). Not surprisingly, interferons are also able to in-
duce expression of the oncogenic fusion protein 
PML-RARα (20; 21). Furthermore, IFN-regulatory 
factor 3 (IRF3) directly regulates PML levels by bind-
ing to the PML promoter. This increased PML tran-
scription is a key regulatory event in the ability of 
IRF3 to promote p53-dependent cellular senescence 
and inhibition of cell growth in both normal and 
U87MG astrocyte cancer cells (22). Moreover, in acti-
vated macrophages, the myeloid cell transcription 
factor, IFN-regulatory factor 8 (IRF8), is required for 
IFN-γ-induced up-regulation of PML (23). These ob-
servations indicate that different cell types may have 
evolved distinct mechanisms mediating IFN-induced 
stimulation of PML transcription. Therefore, 
up-regulation of PML and thus PML NBs is an im-
portant mediator of the IFN response. In addition, the 
STATs have been shown to negatively regulate PML 
expression during mammary ductal morphogenesis. 
Disruption of the expression of PML by either gene 
knockout of Stat6 (leads to increased PML expression) 
or gene knockout of PML disrupted proper mammary 
gland development in mice (24). This work highlights 
the importance of proper regulation of PML for 
maintaining normal cellular responses. 
In a parallel mechanism, there are other intrinsic 
pathways that can up-regulate PML at the transcrip-
tional level. PML can be transcriptionally 
up-regulated by p53. The first intron of PML harbors a 
p53 binding site and p53 is capable of associating with 
this site both in vitro and in vivo. Induction of p53 can 
up-regulate PML expression and increase PML NB 
number and size (25). Furthermore, oncogenic Ras, 
whose downstream effects include up-regulation of 
p53, is also able to induce PML transcription (26; 25). 
Since various cell stimuli can induce interferon sig-
naling or control p53 activity, it is likely that PML 
levels are controlled transcriptionally in a wide range 
of cellular conditions. Together, these data indicate 
that an increase in PML transcription is part of the 
response for a distinct set of pathways that are in-
volved in genome stability, oncogenesis, and viral 
responses. Furthermore, they suggest that PML likely 
plays a role in other intracellular signaling events in 
response to various extracellular stimuli. 
Control of PML through alternative splicing 
PML expression is regulated by the cell or tissue 
type and the differentiation stage of the cell (27-29). 
One of the main contributing factors to this varied 
expression is alternative splicing which results in the 
expression of at least 11 different isoforms (30). The 
human promyelocytic leukemia (PML) gene is located 
across 53,000 bases that compose 9 exons at chromo-
somal location 15q22. Different PML isoforms are de-
rived from alternative splicing of the C-terminal exons 
(5-9) (Figure 1). All PML isoforms maintain the RBCC 
motif in the N-terminal half of the protein, comprised 
of a zinc-finger RING domain followed by two zinc 
finger B Boxes, followed by a coiled-coil domain (30). 
This motif is an important mediator of 
homo-oligomerization of PML as well as interactions 
of PML with other proteins. Since not all PML iso-
forms retain the nuclear localization sequence in exon 
6, there are both nuclear and cytoplasmic PML iso-
forms (30-33). 
Cytoplasmic PML 
One of the major distinctions among PML iso-
forms is their subcellular localization (Figure 2). This 
can be one of the main determinants of their role in 
the cell. It has become clear that the cytoplasmic forms 
are an important area of investigation for both their 
ability to regulate nuclear PML as well as their own 
(cytoplasmic) functions. Cytoplasmic PML can redis-
tribute nuclear PML to the cytoplasm, thus decreasing 
nuclear body formation and size (34; 35). For example, 
this sequestration was shown to lead to inhibition of 
the growth suppressive function of p53, which is 
normally mediated by nuclear PML (34; 35). In this 
manner, the subcellular distribution of certain PML 
isoforms is able to regulate the overall activity of Int. J. Biol. Sci. 2009, 5 
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PML. There is also crosstalk between cytoplasmic 
forms of PML and the TGFβ signaling pathway 
through interactions with its downstream regulators 
Smad2/3 and SARA (36). Furthermore, the ho-
meodomain protein TGIF, which is a negative regu-
lator of TGFβ signaling, is able to sequester cyto-
plasmic PML to the nucleus (37). Interestingly, herpes 
simplex virus -1 (HSV-1) infection leads to a change in 
splicing of PML pre-mRNA resulting in an increased 
ratio of cytoplasmic to nuclear isoforms (38). Overall, 
controlling the subcellular localization of PML ap-
pears to be an important regulatory mechanism for 
PML. Research into the mechanisms that determine 
PML localization may provide one of the most effec-
tive ways by which to therapeutically manipulate 
PML. 
 
 
Figure 1. Domain Structure of PML. The schematic shows all functional domains that are present in PML proteins. This 
schematic is not representative of any specific naturally occurring isoform. The human PML gene is comprised of 9 exons 
that are alternatively spliced into transcripts that encode at least 11 isoforms. All of the isoforms contain exons 1-4, but 
alternative splicing of exons 5-9 leads to variation at the C-terminal ends of the PML isoforms. All isoforms contain the 
N-terminal RBCC (RING/B-Box/Coiled coil) motif, which is important for protein-protein interactions and contains many 
regulatory sites for PML. Most isoforms also contain a nuclear localization sequence (NLS) found in exon 6. 
 
Figure 2. Regulation of PML Protein. The activity of PML is ultimately controlled through its localization and expres-
sion levels. The control of these characteristics of PML can be accomplished through altering binding partners or stability of 
PML that lead to immediate changes (left panel) or by post-translationally modifying PML, which leads to subsequent changes 
in localization and stability indirectly (right panel). Signals to control PML often result from extracellular stimuli, but can also 
originate from interactions with other proteins within the cell. In some cases, a single agent or protein can affect all of these 
modes of regulation; however, in all cases the outcome is an alteration of PML activity. Int. J. Biol. Sci. 2009, 5 
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Post-Translational Modifications of PML 
PML is subject to multiple posttranslational 
modifications including sumoylation, phosphoryla-
tion, ubiquitination, acetylation, and ISGylation. 
These modifications lead to alteration of PML protein 
levels and activity (Figure 2). One of the best charac-
terized of these modifications is sumoylation of PML. 
PML can be modified by Sumo-1 and Sumo-2/3 at 
lysines 65, 160 and 490 (39-41). It has recently been 
shown that these different Sumo modifications can 
have distinct consequences for the sumoylated pro-
tein based on the Sumo used and the length of the 
polysumo chain (42; 43). For example, one report 
suggests that modification of PML specifically by 
Sumo-3 is integral to its nuclear localization (42). Su-
moylation of PML is stimulated by the only known E2 
sumo ligase, Ubc9 (44). Similar to other 
sumo-conjugated proteins, PML can be sumoylated in 
vitro in the absence of E3 ligases. Using in vitro trans-
lated PML as a substrate, the E3 sumo ligase RanBP2 
is capable of promoting PML sumoylation,  but 
whether RanBP2 sumoylates PML in vivo remains 
unclear (45). Furthermore, we have recently shown 
that the TNFα-stimulated association of histone de-
actylase 7 (HDAC7) with PML and its subsequent 
Sumo-1 modification, leads to increased PML NB 
formation (46). Using purified recombinant proteins, 
we demonstrated that HDAC7 potently stimulates 
PML sumoylation with Sumo-1 in a reconstituted 
system. More importantly, knockdown of HDAC7 
abrogates basal and TNFα-induced PML sumoylation 
and reduces PML protein levels and PML NB forma-
tion (12). These data provide a mechanistic link be-
tween PML, its Sumo-1 modification and its stability. 
In support, Sumo1-/- mice express reduced levels of 
PML protein and fewer PML NBs (47). Lastly, as 
mentioned previously, the sumoylation status of PML 
is regulated in a cell cycle-dependent manner. During 
interphase, Sumo-1 is conjugated to PML. PML is 
de-sumoylated once mitosis begins (48).  
De-sumoylation of PML may be an important 
mechanism for the regulation of PML activity, but has 
not been widely investigated. SENP-1, a member of 
the Sumo-specific protease family, appears to de-
crease PML sumoylation after treatment of cells with 
interleukin-6 (IL-6) (49). Similarly, SENP-5 can re-
move Sumo-2 or Sumo-3 from lysines 160 or 490 or 
Sumo-1 or Sumo-3 from lysine 65 in transient trans-
fection assays (50). Surprisingly, despite retention of 
two of the three PML sumoylation sites, sumoylation 
of PML-RARα has only been observed in vitro when 
Sumo1 is overexpressed (39; 44). Differences in PML 
and PML-RARα sumoylation may account for the 
ability of As2O3 to induce degradation of PML-RARα 
more rapidly than PML (51).  
Recent studies indicate that the 
RING-domain-containing ubiquitin E3 ligase, RNF4, 
catalyzes ubiquitination of sumoylated PML and 
PML-RARα. This activity is attributed to its 
Sumo-interacting motifs (SIMs), domains in its 
N-terminus known to interact with the Sumo moeity. 
This ubiquitinylation is required for the 
As2O3-induced PML degradation (52-54). Since PML 
sumoylation plays an important role in regulation of 
PML accumulation and NB dynamics, it is important 
to further understand the mechanisms and control of 
sumoylation of PML in order to alter PML NB forma-
tion under disease situations.  
Phosphorylation is another important 
post-translational modification of PML. PML is 
phosphorylated at multiple sites in response to vari-
ous stimuli, with each phosphorylation having a dis-
tinct effect on PML activity. Interestingly, phos-
phorylation of PML can be directly linked to sumoy-
lation in response to As2O3. Using an in vitro kinase 
assay, it was shown that PML could be phosphory-
lated by the mitogen-activated protein kinase ERK2, 
at threonine 28 and serines 36, 38, 40, 527, and 530. 
Furthermore, As2O3-induced PML phosphorylation at 
some of these sites is ERK2-dependent. Mutation of 
these residues not only prevents phosphorylation but 
also blocks sumoylation of PML. These observations 
led to a model in which the phosphorylation of PML 
is essential for PML sumoylation and As2O3-induced 
apoptosis (6). Although the detailed mechanisms by 
which PML phosphorylation promotes or inhibits 
sumoylation are currently unknown, there is likely 
crosstalk between these two modifications in response 
to extracellular signals.  
Phosphorylation of PML can also regulate PML 
activity independently of sumoylation. In response to 
the DNA-damaging agent doxorubicin, PML accu-
mulates in the nucleolus as part of the S-phase cell 
cycle checkpoint. This nucleolar localization is de-
pendent on phosphorylation of PML by the check-
point kinase ataxia telangiectasia Rad-3 related (ATR) 
kinase, although the site(s) of this phosphorylation are 
unknown (55). In addition, in response to 
γ-irradiation, hCds1/Chk2 phosphorylates PML and 
this phosphorylation is required for 
γ-irradation-induced apoptotsis (56).   
Aside from its roles in the DNA damage re-
sponse and apoptosis, PML is also widely studied as a 
tumor suppressor. This activity can be regulated in a 
phosphorylation-dependent manner. The oncogenic 
kinase, casein kinase 2 (CK2), is able to phosphorylate 
PML on serine 565 and promote pro-Int. J. Biol. Sci. 2009, 5 
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teosome-dependent degradation of PML. Conse-
quently, PML mutants that cannot be phosphorylated 
by CK2 have more potent tumor suppressor proper-
ties, providing a strong link between regulation of 
PML by CK2 and tumorigenesis (57).  
In addition to sumoylation and phosphorylation, 
other PML modifications have been reported. PML 
and PML-RARα are subject to ISGylation by inter-
feron-stimulated gene- 15 (ISG15). Like Sumo, ISG15 
is a small ubiquitin-like peptide that can be conju-
gated to proteins in an E1/E2/E3-dependent manner. 
Expression of the ISG15 conjugation system can be 
stimulated by type-I interferons, bacterial lipopoly-
saccharides, and viral infection. Once expressed, 
ISG15 can be secreted or conjugated to proteins (58). 
Protein ISGylation can affect protein-protein interac-
tions (59; 60) and block other modifications such as 
neddylation (61). In one case, conjugation of ISG15 to 
the eukaryotic translation initiation factor 4E (eIF4E) 
family member 4E-HP (or eIF4E-2) increases the af-
finity of 4E-HP to the mRNA 5’ cap structure, thus 
affecting control of cap-dependent translation (59). 
Interestingly, PML has been shown to interact with 
family member eIF4E (or eIF4E-1) and decrease its 
affinity for mRNA, thus also controlling mammalian 
protein expression. It is not known whether ISGyla-
tion plays a role in this pathway (62). ISGylation of the 
PML domain in PML-RARα has been proposed to 
decrease its accumulation (63). The mechanism by 
which PML ISGylation is regulated is completely 
unknown. Recent work also indicates that PML is 
subject to acetylation. This acetylation appears to 
correlate with increased PML sumoylation and may 
be important in PML-dependent cell death pathways 
(64). Lastly, as previously mentioned, PML is known 
to be ubiquitinylated by RNF4 (52-54). This ubiquiti-
nylation is induced in response to As2O3, which in-
creases sumoylation of PML. Furthermore, since 
many other extracellular signals regulate PML su-
moylation and or PML stability, it is likely that RNF4 
acts downstream of other signals, and that there are 
likely other undiscovered E3 ubiquitin ligases that act 
on PML.  
Post-translational modifications of PML are im-
portant for the regulation of PML protein levels, lo-
calization, and activity and it is likely that there are 
other PML modifications yet to be identified. This 
intricate network of modifications of PML exemplifies 
the elaborate regulation of PML activity in the cell. 
Control of PML Protein Stability 
Several distinct mechanisms have been shown to 
regulate PML protein levels (Figure 2). The mammal-
ian homologues of the Drosophila Seven in Absentia 
(SIAHs) are known to target proteins involved in cell 
growth and tumorigenesis for degradation. Specifi-
cally, mSiah-2 targets PML for proteosome-dependent 
degradation. The decrease in PML protein levels cor-
relates with a decrease in PML NB number. It is pos-
sible that this pathway is part of a regulatory feedback 
loop involving the p53 protein, since p53 can activate 
SIAH-1 transcription (65). PML-RARα, is also subject 
to mSiah-2-mediated degradation; however, ectopic 
overexpression of mSiah-2 only partially rescues the 
differentiation block that is characteristic of APL cells, 
possibly due to residual PML-RARα that is not de-
graded (66). Another p53-dependent pathway, the 
DNA damage response, leads to increased PML pro-
tein levels. Treatment of cells with ionizing radiation 
or cisplatin increases PML protein levels and PML NB 
number and size; however PML mRNA levels are 
unchanged (67). Though the exact mechanism un-
derlying DNA damage-induced increases in PML 
protein is unknown, it may be dependent on a kinase 
activated by ionizing radiation, inhibition of a nega-
tive kinase regulator, or through another cell cycle 
checkpoint regulator such as ATM/Chk2 (68; 69). By 
contrast, androgen leads to down-regulation of PML 
protein levels in the prostate cancer cell line CWR22R. 
Though the detailed mechanism of this degradation 
has yet to be delineated, it has been suggested that the 
decrease in PML protein levels is post-translational 
because little change in the PML mRNA levels was 
observed. Functionally, this data suggests that PML 
may suppress the cell growth of androgen-dependent 
prostate cancers (70). While little is known about the 
regulation of steady-state levels of PML in the absence 
of exogenous signals, work in our lab has shown that 
PML interacts with the peptidyl-prolyl isomerase Pin1 
(13). Interaction with Pin1 results in decreased stabil-
ity of PML. Pin1-mediated PML degradation is likely 
to be blocked by Sumo1 modification since 
Sumo1-modified PML no longer binds to Pin1. Fur-
thermore, while the interaction requires PML phos-
phorylation, the kinases responsible for mediating the 
interaction, as well as the downstream mechanism of 
degradation of PML, are unknown (13). Similarly, 
overexpression of the architectural protein HMGA2 
leads to ubiquitin-dependent degradation of PML 
protein, but whether this is due to a direct interaction 
is currently unknown. The effects of HMGA2 are re-
sponsive to As2O3 and dependent on HMGA2 su-
moylation (71). In summary, these data indicate that 
certain signals and protein-protein interactions can 
promote degradation of PML. 
Viral Regulation of PML 
Findings by several labs suggest that many vi-Int. J. Biol. Sci. 2009, 5 
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ruses target PML to modify its levels, localization or 
activity (Table 1). Viruses can regulate PML through 
multiple mechanisms to promote viral replication. For 
example, several viruses target PML to alter its su-
moylation including human cytomegalovirus and 
herpes simplex virus type I (HSV-1) (72; 73). In many 
cases viral proteins induce decreases in sumoylation 
of PML resulting in disruption of PML stability and 
overall decreases in PML protein levels. Interestingly, 
the targeting of PML is required for the infection and 
survival of HSV-1 (74), a result that implicates an in-
hibitory role for PML in viral replication. Similarly, 
other viral-induced changes in PML modifications 
control PML activity in response to viral infection 
such during adenovirus type 5 infection where slower 
migrating PML species increase while Sumo-1 modi-
fied forms of PML decreases (75; 76).  
Table 1. Viral Proteins that Regulate PML. Many 
viruses have mechanisms that target and control PML. 
Several of these controls occur post-translationally to effect 
PML stability and/or localization. The viral protein com-
ponents that regulate PML are listed in the first column. The 
second column indicates the effect that these proteins have 
on PML. 
Viral Proteins  Effect on PML  Reference
IE1, human cytomega-
lovirus 
Promotes de-sumoylation of 
PML 
(72; 73) 
ICP0, herpes simplex 
virus, type I 
Promotes PML degradation, 
alternative splicing, enriches 
cytoplasmic PML 
(77; 78; 
38) 
ORF75c, murine gam-
maherpesvirus 68 
Promotes PML degradation  (79) 
E4orf3, adenovirus type 5 Disrupts PML NBs  (75; 76) 
Core protein, hepatitis C 
virus 
Interacts with and sequesters 
PML 
(80) 
E7, human papilloma 
virus 
Interacts with PML  (81) 
?, human papilloma virus Increases PML NB number  (82) 
?, human herpes virus 6B  Increases PML expression, 
decreases PML NB number 
(83) 
Pre-integration complex, 
human immunodefi-
ciency virus 
Promotes redistribution of 
PML to the cytoplasm 
(84) 
Z protein, lymphocytic 
choriomeningitis virus 
Promotes redistribution of 
PML to the cytoplasm 
(85) 
EBNA-1, Epstein-barr 
virus 
Promotes PML degradation, 
disrupts PML NBs 
(86) 
 
 
Viruses also directly affect PML stability or ac-
tivity via mechanisms that have not been shown to 
include post-translational modification of PML. These 
include proteosome-dependent degradation of PML 
during infection by murine gammaherpesvirus 68 
(gammaHV68) and direct interaction with PML by the 
hepatitis C virus (HCV) core (80; 79). In both cases the 
functional outcome of modulation of PML is to pro-
mote viral replication. Furthermore, as discussed ear-
lier, changes in the subcellular localization of PML can 
be an important regulator of its activity. Components 
of both human immunodeficiency virus (HIV) and 
lymphocytic choriomeningitis virus (LCMV) can in-
duce redistribution of nuclear PML to the cytoplasm 
(85; 84). 
In certain cases, some viruses appear to stabilize 
or promote PML levels. The human papilloma onco-
protein E7 directly interacts with PML and blocks 
PML-mediated cellular senescence. It is currently 
unknown whether interaction of E7 with PML also 
plays a role in the HPV infection (81). However, recent 
work indicates that the number of PML NBs increases 
during HPV infection of human keratinocytes (82), 
which would indicate a mechanism opposite to that of 
other viruses. Similarly, infection of cells with human 
herpesvirus 6B (HHV-6B) led to increased levels of 
PML protein and mRNA (83).  
Clearly the mechanisms governing these obser-
vations are more complex than can be explained with 
the current understanding of PML NB regulation. 
However, it is clear that targeting PML is a common 
mechanism of viral infection and appears to be re-
quired for viral survival in many cases.  
Regulation of PML in Cancer 
PML is known to act as a potent tumor sup-
pressor not only in APL, but also in other cancers. 
Although PML-/-  mice develop normally, they are 
prone to develop tumors in chemical and physical 
models of carcinogenesis (87). The ability of PML to 
suppress oncogenesis may be due to its ability to 
promote apoptosis by both intrinsic and extrinsic 
pathways (9; 10). Changes in PML localization, levels, 
and activity are likely to be equally important factors 
in the anti-tumorigenic function of PML. PML protein 
expression is reduced or greatly diminished in tumor 
cell lines derived from prostate adenocarcinomas, 
colon adenocarcinomas, breast carcinomas, lung car-
cinomas, lymphomas, CNS tumors, and germ cell 
tumors; however, there is no change in PML tran-
script levels in these cells compared to their normal 
counterparts (88). There are several known mecha-
nisms by which PML levels are decreased in these 
cancers. First, as previously mentioned, decreased 
PML levels in cancer can be altered by phosphoryla-
tion of PML by CK2 (57). There is an inverse correla-
tion between PML protein levels and CK2 activity in 
human lung-cancer derived cell lines. Decreased PML 
levels are also associated with increased tumorigene-
sis in a mouse model of lung cancer.  
Conversely, as previously mentioned IRF3 has 
been shown to directly regulate PML levels by bind-
ing to the PML promoter. This IRF3-induced tran-
scription of PML is a key regulatory event in the Int. J. Biol. Sci. 2009, 5 
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promotion of p53-dependent cellular senescence and 
inhibition of cell growth in U87MG astrocyte cancer 
cells (22).  
Interestingly, PML was recently shown to be 
transcriptionally up-regulated during haematopoiesis 
which correlated with increased PML expression in 
patients with the haematopoietic malignancy chronic 
myeloid leukemia (CML). Furthermore, 
down-regulation of PML levels led to a decrease in 
quiescent leukemia-initiating cells (89). These data 
suggest that up-regulation of PML is a critical event in 
CML. However, it remains to be seen whether this is 
unique to CML or more general to other haematopoi-
etic malignancies. Nonetheless, these data highlight 
the importance for regulated control of PML expres-
sion. 
These examples support the notion that PML is a 
key regulatory factor in tumorigenesis. It will be im-
portant to elucidate the regulatory mechanisms that 
lead to decreased PML levels in cancer cells and what 
role PML plays in cancer progression. Furthermore, 
understanding the normal regulation of PML is cen-
tral to elucidating the mechanisms by which PML is 
de-regulated in many cancers including in APL.   
Conclusions and Perspective 
It appears that PML is tar-
geted by numerous extracellular 
signals both in physiological and 
pathological conditions that result 
in modifications and changes in 
PML levels and function (Figure 3). These signals may 
each control PML independently; however, it is likely 
that some act in a collaborative fashion. There are 
likely several undiscovered enzymes such as kinases, 
phosphatases, E3 ubiquitin ligases, E3 sumo ligases, 
etc. that modify and modulate PML activity. The re-
cent findings that sumo modifications play a role in 
the stability control of PML protein and the newly 
identified PML modifications such as acetylation and 
ISGylation suggest that PML activity is controlled by 
complex regulatory networks. It is probable that these 
modifications affect PML regulation in a combinato-
rial manner. 
Even after more than 15 years of investigation, 
there are still many unanswered questions. For ex-
ample, little is known about regulation of the alterna-
tive splicing of the PML transcript or even the unique 
function of each of the spliced isoforms. Similarly, 
while sumoylation of PML is known to be important 
for NB formation and dynamics, little is known about 
steady-state regulation of PML sumoylation. Even 
more apparent is the lack of mechanistic details on the 
specific role of PML in processes such as the inter-
feron response, DNA damage response, and cell cycle. 
 
 
Figure 3. Controlling PML pro-
tein levels and activity is an 
important mechanism deter-
mining cell fate. Extracellular 
stimuli and other events such as viral 
infection and oncogenesis are known 
to affect PML activity. This regulation 
occurs at five distinct levels: tran-
scriptional, alternative mRNA splic-
ing, post-translational modification, 
subcellular localization, and stability 
control. The exact mechanisms of 
these changes are complex, and often 
include multiple modes of regulating 
PML. The result is a net increase or 
decrease in PML activity in the cell. 
(S= sumoylation, A= acetylation, P= 
phosphorylation, I = ISGylation, U= 
ubiquitinylation) 
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PML appears to play a role in many cellular 
pathways. Disruption of PML NBs will affect these 
pathways and therefore may have profound effects on 
normal cellular function. PML has been implicated in 
several illnesses, most notably viral infection and 
cancer. Interestingly, PML is a common target of vi-
ruses in order to promote viral infection. The reasons 
behind this are likely intimately linked with the abil-
ity of PML to promote apoptosis and arrest cell cycle 
progression. A similar effect is observed in cancer, 
though the causes of the decreased PML expression 
are currently unknown. Other diseases involving 
PML and NBs include those with impaired DNA 
damage responses such as Rothmund-Thomson syn-
drome and Bloom’s Syndrome or several neurode-
generative diseases including ataxia,  Huntington's 
disease and  dentatorubral pallidoluysian atrophy 
(90).  
It is of interest that PML-/- mice appear to de-
velop and survive relatively normally. However, re-
cent reports demonstrate that perturbing PML does, 
in fact, affect normal cellular functioning. For exam-
ple, alteration of PML expression resulted in abnor-
mal mammary gland development in mice (24). Fur-
thermore, PML expression is found exclusively in the 
neural progenitor cells of the developing mouse neo-
cortex. Loss of this expression led to defects in the 
ratio of progenitor types and ultimately effected adult 
brain development (91). It is likely that introduction of 
PML expression into other cells in the developing 
brain may also have deleterious effects.  Many pro-
gresses from other labs and ours have shown that 
changes in PML activity or expression levels have 
been found occur in response to extracellular signals 
or can be modified by such. Furthermore, the diseases 
in which PML plays a role are diseases that have de-
fects in “response-driven” pathways, such as those 
impaired in DNA damage, inflammation, or in condi-
tions such as cancer or viral infection where normal 
cellular signaling is disrupted by other means. Under 
these circumstances, changes in PML levels or activity 
are found to be important. Therefore, by modulating 
the PML activities or expression levels during cellular 
stress caused by aberrant cellular signaling, one may 
be able to partially alleviate some of the symptoms of 
these diseases. Armed with new understanding of the 
mechanisms underlying PML regulation, we are one 
step closer to effectively manipulating NBs for thera-
peutic purposes or disease prevention. 
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